Antagonists of the neurokinin-1 or dopamine D1 receptors confer protection from methamphetamine on dopamine terminals of the mouse striatum

Annals of the New York Academy of Sciences

Volumn 1025, Issue , 2004, Pages 171-180

  Angulo, Jesus A ^a   Angulo, Nieves ^a   Jing, Y U ^a  

^a CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

Dopamine D1 receptor; Neurokinin 1 receptor; SCH 23390; Striatum; Substance P; WIN 51,708

Indexed keywords

17ALPHA ETHYNYL 17BETA HYDROXY 5ALPHA ANDROSTANO[3,2 B]PYRIMIDO[1,2 A]BENZIMIDAZOLE; 3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID ISOPROPYL ESTER; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE TRANSPORTER; GREEN FLUORESCENT PROTEIN; IODINE 125; METHAMPHETAMINE; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; POSTSYNAPTIC RECEPTOR; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ASTROCYTE; AUTORADIOGRAPHY; CAUDATE NUCLEUS; CONFERENCE PAPER; DRUG EXPOSURE; DRUG RECEPTOR BINDING; LETHAL DOSE; MALE; MOUSE; MOUSE STRAIN; NEOSTRIATUM; NERVE ENDING; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; NUCLEUS ACCUMBENS; PUTAMEN; WESTERN BLOTTING;

ANIMALIA;

EID: 10444278141     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1316.022     Document Type: Conference Paper

References (38)

1. LUKAS, S. 1997. Proceedings of the National Concensus Meeting on the use, abuse and sequelae of abuse of menthaphetamine with implications for prevention, treatment and research. DHHS Publication SMA96-8013.
2. NATIONAL INSTITUTE ON DRUG ABUSE. 1999. Methamphetamine abuse alert. NIDA: 15-16. Washington, DC.
3. CAREY, J.T. & J. MANDEL. 1968. A San Francisco Bay Area "speed" scene. J. Health Soc. Behav. 9: 164-174.
4. ELLINWOOD, E.H., JR. 1971. Assault and homicide associated with amphetamine abuse. Am. J. Psychiatry 127: 1170-1175.
5. HAWKS, D. et al. 1969. Abuse of methylamphetamine. Br. Med. J. 1: 715-721.
6. SZUSTER, R.R. 1990. Methamphetamine in psychiatric emergencies. Hawaii Med. J. 49: 389-391.
7. FLECKENSTEIN, A.E., J.W. GIBB & G.R. HANSON. 2000. Differential effects of stimulants on monoaminergic transporters: pharmacological consequences and implications for neurotoxicity. Eur. J. Pharmacol. 406: 1-13.
8. SELF, D.W. & E.J. NESTLER. 1995. Molecular mechanisms of drug reinforcement and addiction. Annu. Rev. Neurosci. 18: 463-495.
9. WHITE, F.J. & P.W. KALIVAS. 1998. Neuroadaptations involved in amphetamine and cocaine addiction. Drug Alcohol Depend. 51: 141-153.
10. LOREZ, H. 1981. Fluorescence histochemistry indicates damage of striatal dopamine nerve terminals in rats after multiple doses of methamphetamine. Life Sci. 28: 911-916.
11. RICAURTE, G.A. et al. 1983. Fluoxetine increases long-lasting neostriatal dopamine depletion after administration of d-methamphetamine and d-amphetamine. Neuropharmacology 22: 1165-1169.
12. RICAURTE, G.A. et al. 1984. Nerve terminal degeneration after a single injection of D-amphetamine in iprindole-treated rats: relation to selective long-lasting dopamine depletion. Brain Res. 291: 378-382.
13. RICAURTE, G.A., C.R. SCHUSTER & L.S. SEIDEN. 1980. Long-term effects of repeated methylamphetamine administration on dopamine and serotonin neurons in the rat brain: a regional study. Brain Res. 193: 153-163.
14. PU, C. & C.V. VORHEES. 1995. Protective effects of MK-801 on methamphetamine-induced depletion of dopaminergic and serotonergic terminals and striatal astrocytic response: an immunohistochemical study. Synapse 19: 97-104.
15. FRIEDMAN, S.D., E. CASTANEDA & G.K. HODGE. 1998. Long-term monoamine depletion, differential recovery, and subtle behavioral impairment following methamphetamine-induced neurotoxicity. Pharmacol. Biochem. Behav. 61: 35-44.
16. HOTCHKISS, A.J. & J.W. GIBB. 1980. Long-term effects of multiple doses of methamphetamine on tryptophan hydroxylase and tyrosine hydroxylase activity in rat brain. J. Pharmacol. Exp. Ther. 214: 257-262.
17. HANSON, G.R. et al. 1998. Methamphetamine-induced rapid and reversible reduction in the activities of tryptophan hydroxylase and dopamine transporters: oxidative consequences? Ann. N.Y. Acad. Sci. 844: 103-107.
18. WOOLVERTON, W.L. et al. 1989. Long-term effects of chronic methamphetamine administration in rhesus monkeys. Brain Res. 486: 73-78.
19. SONSALLA, P.K., W.J. NICKLAS & R.E. HEIKKILA. 1989. Role for excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity. Science 243: 398-400.
20. MAGGI, C.A. 1995. The mammalian tachykinin receptors. Gen. Pharmacol. 26: 911-944.
21. YU, J., J.L. CADET & J.A. ANGULO. 2002. Neurokinin-1 (NK-1) receptor antagonists abrogate methamphetamine-induced striatal dopaminergic neurotoxicity in the murine brain. J. Neurochem. 83: 613-622.
22. MANTYH, P.W. et al. 1995. Rapid endocytosis of a G protein-coupled receptor: Substance P evoked internalization of its receptor in the rat striatum in vivo. Proc. Natl. Acad. Sci. USA 92: 2622-2626.
23. ANGULO, J.A. & B.S. MCEWEN. 1994. Molecular aspects of neuropeptide regulation and function in the corpus striatum and nucleus accumbens. Brain Res. Brain Res. Rev. 19: 1-28.
24. NOAILLES, P.-A.H. & J.A. ANGULO. 2002. Neurokinin receptors modulate the neurochemical actions of cocaine. Ann. N.Y. Acad. Sci. 965: 267-273.
25. KRAFT, M., P. NOAILLES & J.A. ANGULO. 2001. Substance P modulates cocaine-evoked dopamine overflow in the striatum of the rat brain. Ann. N.Y Acad. Sci. 937: 121-131.
26. TSAO, L.I. et al. 1998. Delta opioid peptide [D-Ala2,D-leu5]enkephalin blocks the long-term loss of dopamine transporters induced by multiple administrations of methamphetamine: involvement of opioid receptors and reactive oxygen species. J. Pharmacol. Exp. Ther. 287: 322-331.
27. DENG, X. et al. 1999. Null mutation of c-fos causes exacerbation of methamphetamine-induced neurotoxicity. J. Neurosci. 19: 10107-10115.
28. LIU, H. et al. 1999. Substance P is expressed in hippocampal principal neurons during status epilepticus and plays a critical role in the maintenance of status epilepticus. Proc. Natl. Acad. Sci. USA 96: 5286-5291.
29. SNIDER, B.J. & D.W. CHOI. 2002. Glutamate and neurotoxicity. In Glutamate and Addiction. B. H. Herman, Ed.: 51-61. Humana Press, Totowa, NJ.
30. LIU, H. et al. 1999. Resistance to excitotoxin-induced seizures and neuronal death in mice lacking the preprotachykinin A gene. Proc. Natl. Acad. Sci. USA 96: 12096-12101.
31. SONSALLA, P.K., D.E. RIORDAN & R.E. HEIKKILA. 1991. Competitive and noncompetitive antagonists at N-methyl-D-aspartate receptors protect against methamphetamine-induced dopaminergic damage in mice. J. Pharmacol. Exp. Ther. 256: 506-512.
32. O'DELL, S.J., F.B. WEIHMULLER & J.F. MARSHALL. 1992. MK-801 prevents methamphetamine-induced striatal dopamine damage and reduces extracellular dopamine overflow. Ann. N.Y. Acad. Sci. 648: 317-319.
33. NASH, J.F. & B.K. YAMAMOTO. 1992. Methamphetamine neurotoxicity and striatal glutamate release: comparison to 3,4-methylenedioxymethamphetamine. Brain Res. 581: 237-243.
34. STEPHANS, S.E. & B.K. YAMAMOTO. 1994. Methamphetamine-induced neurotoxicity: roles for glutamate and dopamine efflux. Synapse 17: 203-209.
35. YAMAMOTO, B.K. & W. ZHU. 1998. The effects of methamphetamine on the production of free radicals and oxidative stress. J. Pharmacol. Exp. Ther. 287: 107-114.
36. KONRADI, C., J.C. LEVEQUE & S.E. HYMAN. 1996. Amphetamine and dopamine-induced immediate early gene expression in striatal neurons depends on postsynaptic NMDA receptors and calcium. J. Neurosci. 16: 4231-4239.
37. O'DELL, S.J., F.B. WEIHMULLER & J.F. MARSHALL. 1993. Methamphetamine-induced dopamine overflow and injury to striatal dopamine terminals: attenuation by dopamine D1 or D2 antagonists. J. Neurochem. 60: 1792-1799.
38. SONSALLA, P.K., J.W. GIBB & G.R. HANSON. 1986. Roles of D1 and D2 dopamine receptor subtypes in mediating the methamphetamine-induced changes in monoamine systems. J. Pharmacol. Exp. Ther. 238: 932-937.